lambrolizumab
Showing 1 - 25 of 200
Recurrent Glioblastoma, Recurrent Gliosarcoma Trial in Houston (other, biological, procedure)
Active, not recruiting
- Recurrent Glioblastoma
- Recurrent Gliosarcoma
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 19, 2022
Lung Non-Small Cell Carcinoma Trial in Buffalo (Pembrolizumab)
Active, not recruiting
- Lung Non-Small Cell Carcinoma
- Pembrolizumab
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 27, 2023
Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker
Active, not recruiting
- Follicular Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 6, 2022
Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Houston
Terminated
- Locally Advanced Malignant Solid Neoplasm
- +2 more
- Pembrolizumab
- Pevonedistat
-
Houston, TexasM D Anderson Cancer Center
Dec 22, 2022
Melanoma Trial in Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)
Recruiting
- Melanoma
- Fianlimab
- +3 more
-
Knoxville, TennesseeUniversity of Tennessee Medical Center
Dec 20, 2022
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 Trial in Chicago
Terminated
- Pancreatic Adenocarcinoma
- +2 more
- Pembrolizumab
- Wild-type Reovirus
-
Chicago, IllinoisNorthwestern University
Sep 6, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 Trial in San Francisco (Pembrolizumab,
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Pembrolizumab
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 5, 2023
Metastatic Malignant Tumor in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma Trial in
Active, not recruiting
- Metastatic Malignant Neoplasm in the Bone
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 4, 2023
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 Trial in Jacksonville (drug,
Active, not recruiting
- Metastatic Melanoma
- +3 more
- Imiquimod
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Jan 3, 2023
Colorectal Tumors, Microsatellite Instability Trial in Milano, Rozzano (temozolomide (induction),, pembrolizumab (treatment))
Recruiting
- Colorectal Neoplasms
- Microsatellite Instability
- temozolomide (induction),
- pembrolizumab (treatment)
-
Milano, Italy
- +3 more
Sep 28, 2022
Thymoma, Thymic Cancer Trial in Houston (Pembrolizumab)
Recruiting
- Stage III Thymoma AJCC v8
- +6 more
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Nov 11, 2022
Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)
Terminated
- Hodgkin's Lymphoma
- Pembrolizumab
- Umbralisib
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 22, 2022
Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Malignant Solid Neoplasm
- Alisertib
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- +2 more
- Azacitidine
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)
Recruiting
- Locally Advanced Malignant Solid Neoplasm
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Mar 22, 2022
Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage III Bladder Cancer AJCC v8 Trial in Houston
Active, not recruiting
- Stage I Bladder Cancer AJCC v8
- +4 more
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Oct 20, 2022
Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in
Recruiting
- Advanced Hepatocellular Carcinoma
- +4 more
- Futibatinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 30, 2023
Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma Trial in Seattle
Terminated
- Advanced Hepatocellular Carcinoma
- +2 more
- Cabozantinib S-malate
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 12, 2022
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression Trial in Portland (drug, other,
Active, not recruiting
- Castration-Resistant Prostate Carcinoma
- +4 more
- Enzalutamide
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Sep 26, 2022
Thymic Carcinoma Trial in Columbus (other, biological, drug)
Recruiting
- Thymic Carcinoma
- Laboratory Biomarker Analysis
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 27, 2022
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,
Active, not recruiting
- Metastatic Melanoma
- +6 more
- Ibrutinib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 13, 2023
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial (radiation, biological, procedure)
Withdrawn
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Copper Cu 64-DOTA-pembrolizumab
- +2 more
- (no location specified)
Jun 7, 2022
Hormone-Resistant Prostate Cancer, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Soft Tissues Trial
Active, not recruiting
- Hormone-Resistant Prostate Cancer
- +6 more
- Pembrolizumab
- pTVG-HP Plasmid DNA Vaccine
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Nov 8, 2022
Colorectal Cancer, Colorectal Cancer Metastatic Trial in United States (Pembrolizumab, Regorafenib)
Active, not recruiting
- Colorectal Cancer
- Colorectal Cancer Metastatic
- Pembrolizumab
- Regorafenib
-
Duarte, California
- +3 more
Aug 5, 2022